LGND Short Volume
Ligand Pharmaceuticals Incorporated (LGND) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $6.08B, listed on NASDAQ, employing roughly 68 people, carrying a beta of 1.04 to the broader market. Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Led by Todd C. Davis, public since 1992-11-18.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-06-30
- Short Volume
- 259.7K
- Total Volume
- 402.6K
- Short %
- 64.49%
- 30-Day Avg Short %
- 77.05%
Showing 30 days of FINRA short volume data for Ligand Pharmaceuticals Incorporated.
Learn how short volume is reported and how to read the data →
Frequently asked LGND short volume questions
- What is the daily LGND short volume?
- As of Jun 30, 2026, Ligand Pharmaceuticals Incorporated (LGND) short volume is 259.7K shares against 402.6K total reported volume, or 64.49% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is LGND short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does LGND short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.